Advanced Life Sciences, a biopharmaceutical company that develops drugs to treat infectious disease, inflammation, and oncology, priced 7.0 million shares at $5 Thursday night. The company originally planned to offer 4.5 million shares at a range of $11-$13. CE Unterberg Towbin will be the lead manager on the deal. Expect shares to begin trading today on the NASDAQ under the symbol "ADLS."
